Humanin Peptide Research: The Complete Guide to the First Mitochondrial-Derived Peptide
Shop Our Top Compounds
Humanin Peptide Research: The Complete Guide to the First Mitochondrial-Derived Peptide
All compounds discussed in this article are intended for research purposes only and are not for human consumption. The information presented reflects published scientific literature and does not constitute medical advice or treatment guidance.
Introduction: A Paradigm-Shifting Discovery in Peptide Science
In 2001, a research team led by Hashimoto and colleagues made a remarkable discovery while screening a cDNA library derived from the surviving fraction of an Alzheimer’s disease patient’s brain. They identified a novel 24-amino acid peptide, encoded within the mitochondrial genome, that demonstrated powerful neuroprotective properties against a wide spectrum of familial Alzheimer’s disease-related insults. They named it humaninβa deliberate tribute to the molecule’s potential to restore the βhumanityβ of patients with neurodegenerative disease (Hashimoto et al., 2001).
This discovery was groundbreaking for multiple reasons. Not only did it reveal a previously unknown class of biologically active peptides originating from the mitochondrial genomeβnow termed mitochondrial-derived peptides (MDPs)βbut it also fundamentally challenged the longstanding assumption that the small mitochondrial genome encoded only 13 structural proteins essential for oxidative phosphorylation. Humanin peptide research has since expanded into an extraordinary range of fields, from neuroscience and cardiovascular medicine to metabolic disease and aging biology.
Today, humanin stands as the founding member of a growing superfamily of MDPs that includes MOTS-c and the small humanin-like peptides (SHLPs 1β6). Research into this remarkable neuroprotective peptide has produced hundreds of peer-reviewed publications, revealing mechanisms of cytoprotection that span multiple signaling pathways and organ systems. This comprehensive guide examines the current state of humanin peptide research, including its discovery, molecular mechanisms, therapeutic potential across disease models, and the emerging MDP superfamily.
Discovery and Molecular Characterization of Humanin
The Hashimoto Discovery: Screening for Neuronal Survival Factors
The origin of humanin peptide research traces to an unbiased functional screen conducted by the Nishimoto laboratory at Keio University in Japan. The researchers constructed a cDNA library from the occipital lobe of an autopsied Alzheimer’s disease (AD) patientβspecifically, from brain regions that remained unaffected by neurodegeneration. By screening for clones capable of protecting neuronal cells from cell death induced by amyloid precursor protein (APP) mutants associated with early-onset familial AD, they identified multiple clones whose sequences mapped to the mitochondrial 16S ribosomal RNA (rRNA) gene (Hashimoto et al., 2001).
Further analysis revealed a 75-base pair open reading frame (ORF) within the 16S rRNA gene that encodes a 24-amino acid polypeptide. The resulting peptide sequenceβMAPRGFSCLLLLTSEIDLPVKRRAβwas designated as humanin (HN). The peptide was subsequently detected in circulation, in tissues, and in cell culture media from transfected neuronal cells, indicating that humanin possesses secretory capacity despite its small size.
Mitochondrial Genome Origin: The 16S rRNA Connection
Humanin is encoded within the mitochondrial genome (gene designation: MT-RNR2), located specifically as a small ORF nested within the 16S rRNA gene. This is remarkable because the human mitochondrial genomeβa compact circular DNA molecule of approximately 16,570 base pairsβwas previously believed to encode only 13 proteins, 22 transfer RNAs, and 2 ribosomal RNAs, all essential for oxidative phosphorylation.
An important aspect of humanin biology is its unique translational ambiguity. Because mitochondria employ a slightly different genetic code from cytoplasmic translation machinery, the same nucleotide sequence can theoretically produce distinct peptides depending on whether translation occurs in the mitochondrion or the cytoplasm. Research has demonstrated that humanin synthesized using both mitochondrial and cytoplasmic genetic codes retains biological activity, and the precise translational site remains a subject of active investigation (Lee et al., 2013).
Strong evidence supports a genuine mitochondrial origin for humanin. Northern blot analyses demonstrated that the humanin ORF hybridizes to RNA from HeLa cells at a size identical to mitochondrial 16S rRNA, while Ο0 HeLa cellsβwhich lack mitochondrial DNAβshow no significant hybridization. Additionally, N-terminally formylated humanin displays enhanced receptor affinity, and N-terminal formylation is a hallmark of mitochondrially translated proteins (Lee et al., 2013).
Structural Features and Conservation
Humanin is highly conserved across species, with homologs identified in organisms as distant as nematodes (C. elegans), suggesting it represents an ancient mitochondrial signaling molecule. The interspecies sequence similarity is approximately 92% in rhesus monkeys, 73% in mice, and 75% in naked mole-rats relative to the human sequence (Yen et al., 2020). This extraordinary conservation underscores the functional importance of humanin throughout evolutionary history.
The peptide contains a pseudo-signal peptide domain that enables its secretion from cells via endoplasmic reticulumβGolgi transport processes. Once secreted, humanin acts as both an autocrine/paracrine factor and an endocrine signal, with measurable levels detected in human plasma, cerebrospinal fluid, and multiple tissue types.
Cytoprotective Mechanisms of Humanin
Humanin exerts its cytoprotective effects through multiple intracellular and extracellular pathways, making it one of the most versatile protective peptides discovered to date. Research has characterized at least four major mechanistic axes through which humanin signals.
BAX Antagonism: Blocking the Apoptotic Cascade
One of the earliest and most important mechanistic discoveries in humanin peptide research came from Guo et al. (2003), who identified humanin as a direct binding partner of the pro-apoptotic protein BAX through a yeast two-hybrid screen. BAX is a central mediator of the intrinsic apoptotic pathway; upon activation, it translocates to the mitochondrial outer membrane, where it oligomerizes to form pores that release cytochrome c and trigger caspase-dependent cell death.
Research has demonstrated that humanin binds directly to BAX, preventing its translocation to the mitochondria and subsequent activation. The humanin-BAX complex is retained in the cytoplasm, effectively neutralizing BAX’s pro-apoptotic function. Additionally, humanin binds to other BH3-domain proteins including Bid and BimEL, further broadening its anti-apoptotic repertoire (Luciano et al., 2005).
In published studies, researchers observed that humanin suppresses staurosporine-induced BAX activation and the subsequent release of cytochrome c into the cytoplasm. These findings position humanin as a potent intracellular guardian against mitochondria-dependent apoptosis.
IGFBP-3 Binding: Modulating the IGF Axis
A second independent research group, led by Cohen and colleagues, cloned humanin through a yeast two-hybrid screen as a high-affinity binding partner of insulin-like growth factor-binding protein 3 (IGFBP-3). IGFBP-3 serves dual roles in cellular biology: it regulates IGF bioactivity by binding and sequestering IGF-I, and it independently induces apoptosis and inhibits cell growth through IGF-independent mechanisms (Ikonen et al., 2003).
Research demonstrated that humanin binds to the heparin-binding domain of IGFBP-3 with high affinity and specificity, thereby antagonizing IGFBP-3-induced apoptosis. Importantly, humanin does not interfere with IGF-I/IGFBP-3 binding, suggesting it occupies a distinct binding site and modulates a separate functional axis of IGFBP-3 biology. This interaction has significant implications for understanding humanin’s role in metabolic regulation, as the IGF system is a central mediator of growth, metabolism, and aging.
STAT3 Signaling: The Trimeric Receptor Complex
Extracellularly, humanin signals through at least two distinct cell-surface receptor systems. The first is a trimeric receptor complex consisting of ciliary neurotrophic factor receptor Ξ± (CNTFR), the cytokine receptor WSX-1, and the transmembrane glycoprotein gp130 (Hashimoto et al., 2009). This receptor complex belongs to the interleukin-6 (IL-6) receptor family and activates the JAK/STAT3 signaling cascade.
In published investigations, researchers demonstrated that humanin coprecipitates with CNTFR and WSX-1, and promotes hetero-oligomerization of the trimeric receptor complex. siRNA-mediated knockdown of either CNTFR or WSX-1 abolishes humanin-dependent cytoprotection against Alzheimer’s disease-related insults, confirming the functional importance of this signaling pathway. STAT3 activation is required for many of humanin’s neuroprotective and metabolic effects.
FPRL1 Activation: The G-Protein-Coupled Receptor Pathway
The second extracellular receptor for humanin is the formyl-peptide receptor-like-1 (FPRL1), a seven-transmembrane G-protein-coupled receptor linked to Alzheimer’s disease pathology. Research by Ying et al. (2004) showed that both the amyloid-Ξ²42 peptide and humanin can activate FPRL1, but only AΞ²42 is cytotoxic. Humanin’s cytoprotection may involve competitive binding to FPRL1, displacing amyloid-Ξ² and activating ERK1/2 signaling and intracellular calcium mobilization instead.
The existence of these dual receptor systems likely explains humanin’s remarkably diverse biological effects across different cell types and tissue contexts. For researchers exploring peptide signaling mechanisms, Iron Peak Peptides offers research-grade humanin for laboratory investigation.
Alzheimer’s Disease Research: Humanin’s Neuroprotective Properties
Alzheimer’s disease research was the original context for humanin’s discovery, and this remains one of the most extensively studied areas of humanin peptide research.
Protection Against Amyloid-Ξ² Toxicity
The earliest humanin studies demonstrated robust protection against neuronal cell death induced by amyloid-Ξ² (AΞ²) peptides, mutant amyloid precursor protein (APP), and presenilin 1 and 2 (PS1/2) mutations associated with familial AD. In published studies, researchers treated F11 neuronal cells with AΞ²1β43 at concentrations of 25 ΞΌM and observed that co-treatment with humanin effectively prevented neuronal death as assessed by trypan blue exclusion and WST-8 assays (Hashimoto et al., 2001).
Subsequent research revealed that humanin and its analogs exhibit chaperone-like activity, specifically targeting misfolded amyloid seeds to inhibit protein misfoldingβa mechanism that may be relevant not only to AD but to other amyloidogenic diseases (Okada et al., 2017).
Cognitive Improvements in Animal Models
Multiple research groups have demonstrated that humanin and its analogs improve cognitive outcomes in AD animal models. In a triple-transgenic AD mouse model (3xTg-AD) harboring APPswe, tauP310L, and PS-1M146V mutations, the humanin derivative S14G-humanin (HNG) reduced amyloid-Ξ² accumulation and ameliorated memory deficits. Similarly, in middle-aged APPswe/PS1dE9 double-transgenic mice, HNG improved cognitive deficits and reduced amyloid pathology (Niikura et al., 2011).
Research has also shown that humanin levels in the cerebrospinal fluid of AD patients are significantly lower compared to age-matched controls, further supporting the hypothesis that humanin deficiency may contribute to neurodegeneration (Yen et al., 2020).
Tau Phosphorylation and Neuroinflammation
Beyond amyloid-Ξ², humanin peptide research has explored effects on tau pathology and neuroinflammationβtwo other hallmarks of AD. Published studies have demonstrated that S14G-humanin ameliorates AΞ²25β35-induced behavioral deficits in mice by reducing neuroinflammatory responses and neuronal apoptosis. Bi-weekly injections of HNG in aging mice delayed age-related cognitive decline and decreased inflammatory markers including IL-6 and Iba-1 (Yen et al., 2018).
Cardiovascular Protection: Atherosclerosis, Endothelial Function, and Ischemia
Atherosclerosis Prevention
Cardiovascular research represents one of the most promising applications of humanin peptide research. In a landmark study, Oh et al. (2011) treated ApoE-deficient mice fed a high-cholesterol diet with the humanin analog HNGF6A for 16 weeks. The investigators observed a dramatic decrease in atherosclerotic plaque size, preserved endothelial function, and improved expression of endothelial nitric oxide synthase (eNOS) in the aorta. The study concluded that anti-oxidative stress, anti-apoptosis, and eNOS preservation are mechanisms partially responsible for humanin’s protection against atherosclerosis.
Endothelial Function and Vascular Biology
Research by Bachar et al. (2010) demonstrated that humanin is endogenously expressed in human vascular walls and exerts cytoprotective effects against oxidized LDL-induced oxidative stress in human aortic endothelial cells. Furthermore, circulating humanin levels have been associated with preserved coronary endothelial function in human subjects, suggesting that humanin serves as both a local and systemic vascular protectant.
Ischemia-Reperfusion Injury
In cardiac ischemia-reperfusion (I/R) injury models, acute humanin therapy with the HNG analog significantly attenuated myocardial damage. Muzumdar et al. (2010) demonstrated that in a mouse model of cardiac I/R injuryβ45 minutes of left coronary artery occlusion followed by 24-hour reperfusionβhumanin therapy reduced infarct size and preserved cardiac function. The protective mechanism involved attenuation of mitochondrial dysfunction and reduction of oxidative stress markers, consistent with humanin’s known cytoprotective activities.
These cardiovascular findings suggest that humanin may serve both as a biomarker for mitochondrial function in cardiovascular disease and as a potential pharmacological strategy in endothelial dysfunction. Researchers investigating cardiovascular peptide mechanisms can explore IronPeak’s research peptide catalog for laboratory-grade compounds.
Metabolic Research: Insulin Sensitization and Glucose Metabolism
Central and Peripheral Insulin Action
Humanin’s metabolic effects have been extensively characterized in multiple diabetes models. Muzumdar et al. (2009) demonstrated that both peripheral intravenous and central intracerebroventricular (ICV) infusion of humanin and its analogs significantly improved overall insulin sensitivity in rats. This effect was mediated in part by hypothalamic STAT3 activation through the trimeric CNTFR/WSX-1/gp130 receptor complex.
In published euglycemic clamp studies, ICV humanin administration produced a significant reduction in hepatic glucose productionβan indicator of improved hepatic insulin sensitivityβcoupled with increased peripheral glucose uptake. Remarkably, a single treatment with the potent humanin analog HNGF6A normalized blood glucose levels in Zucker diabetic fatty rats, a well-established model of type 2 diabetes.
Beta-Cell Protection and Type 1 Diabetes Models
In NOD miceβa model of autoimmune type 1 diabetes involving progressive lymphocytic infiltration of pancreatic isletsβhumanin treatment improved glucose tolerance and delayed diabetes onset. Hoang et al. (2010) demonstrated that humanin dramatically suppressed pancreatic inflammation and lymphocyte infiltration while protecting NIT-1 pancreatic Ξ²-cells from cytokine-induced apoptosis in an ERK- and STAT3-dependent manner. These findings suggest humanin may serve as an islet-protective factor with relevance to autoimmune Ξ²-cell destruction.
Clinical Correlations
Clinical studies have found that circulating humanin levels are negatively correlated with HbA1c and triglyceride levels in human subjects, and that mitochondrial-derived peptide levels are significantly reduced in diabetic patients compared to healthy controls. These correlations further support the hypothesis that humanin plays a physiologically relevant role in metabolic homeostasis.
Anti-Aging and Longevity Research
Centenarian Studies: Elevated Humanin in Exceptional Longevity
Some of the most compelling data linking humanin to longevity come from studies of human centenarians and their offspring. In a landmark study by Yen et al. (2020), the children of centenariansβwho have a higher probability of becoming centenarians themselvesβdemonstrated significantly higher circulating humanin levels compared to age-matched controls (N=18 and 19, respectively). This finding directly links elevated humanin levels with exceptional human longevity and reduced disease burden.
Age-Related Decline Across Species
Research has consistently demonstrated that humanin levels decline with age across multiple species. In mice, circulating humanin decreased by approximately 40% over the first 18 months of life. In rhesus macaques, a dramatic decline was observed between 19 and 25 years of age. In humans, circulating levels gradually decline across age groups from 45β65, 66β80, and 81β100 years (Muzumdar et al., 2009; Lee et al., 2013).
The Naked Mole-Rat Exception
Particularly intriguing findings emerged from the study of naked mole-rats (Heterocephalus glaber), the longest-lived rodent species (>30 years) exhibiting negligible senescence. Unlike mice, naked mole-rats show remarkably stable humanin levels over more than two decades, with basal levels approximately 4-fold higher than those in young mice. Given this species’ extraordinary resistance to age-related disease and constant mortality rate throughout life, the sustained humanin levels may be a key component of their negligible senescence phenotype (Yen et al., 2020).
Lifespan Extension in Model Organisms
Direct experimental evidence for humanin’s role in lifespan extension comes from C. elegans studies. Yen et al. (2020) demonstrated that transgenic worms overexpressing humanin exhibited a small but consistent and significant increase in lifespan compared to wild-type controls. This lifespan extension was dependent on daf-16/FOXOβa transcription factor central to the insulin/IGF-1 signaling pathway that regulates longevity across species. The humanin-overexpressing worms also displayed decreased body size, body fat, and reproductive outputβphenotypes consistent with other longevity models.
Cancer Research Context: The Dual Role of Cytoprotection
The relationship between humanin and cancer is complex, reflecting a dual-edged sword inherent to potent cytoprotective molecules.
Cytoprotection as a Double-Edged Sword
Humanin’s powerful anti-apoptotic mechanismsβBAX antagonism, IGFBP-3 binding, and STAT3 activationβprotect healthy cells from stress-induced death. However, these same mechanisms can theoretically promote tumor cell survival and chemoresistance. Published research has demonstrated that humanin can promote tumor progression in experimental triple-negative breast cancer models and facilitate chemoresistance by protecting cancer cells from apoptosis.
Protective Effects During Chemotherapy
Conversely, research by Lue et al. (2015) demonstrated that the potent humanin analog HNG protects normal germ cells and leukocytes from the toxic effects of cyclophosphamide chemotherapy while simultaneously enhancing chemotherapy-induced suppression of cancer metastases in male mice. This suggests a potentially nuanced role where humanin preferentially protects normal tissues during chemotherapy without compromising anti-tumor efficacyβa finding of considerable therapeutic interest.
The cancer research context underscores the importance of continued investigation into cell-type-specific responses to humanin and the need for careful consideration of cytoprotective peptides in oncological research settings.
Synthetic Analogs: HNG, Colivelin, and Enhanced-Potency Variants
HNG (S14G-Humanin): 1,000-Fold Enhanced Potency
The development of synthetic humanin analogs has been critical for advancing humanin peptide research. The most widely studied analog is HNG (S14G-humanin), which features a single amino acid substitution at position 14 (glycine replacing serine). This modification increases biological potency by approximately 1,000-fold compared to native humanin, making it practical for in vivo research applications where native humanin’s short half-life (approximately 30 minutes) is a limitation.
HNGF6A: Non-IGFBP-3 Binding Variant
The analog HNGF6A combines two substitutions: the S14G potency-enhancing mutation and an F6A substitution (alanine for phenylalanine at position 6) that abrogates IGFBP-3 binding. This double-mutant analog has been instrumental in dissecting humanin’s IGFBP-3-dependent versus IGFBP-3-independent activities. HNGF6A has demonstrated dramatic metabolic effects, including normalization of blood glucose in diabetic rat models and prevention of atherosclerotic plaque progression.
Colivelin: A Hybrid Neuroprotective Peptide
Colivelin is a hybrid peptide that fuses a partial humanin sequence with activity-dependent neurotrophic factor (ADNF) sequences, producing a compound with enhanced neuroprotective potency. In published studies, colivelin prolonged survival in an ALS mouse model expressing the mutant G93A-SOD1 gene, demonstrating therapeutic potential beyond Alzheimer’s disease.
Rattin: The Rodent Homolog
Rattin is the rat mitochondrial homolog of humanin, differing by a single amino acid from the human sequence. Its identification confirmed the evolutionary conservation of humanin and enabled extensive rodent studies that have been fundamental to characterizing humanin’s in vivo pharmacology.
For researchers interested in humanin analogs and related neuroprotective peptides, Iron Peak Peptides provides high-purity research compounds with quality assurance.
The MDP Superfamily: MOTS-c, SHLPs, and the Expanding Mitochondrial Peptidome
MOTS-c: The Exercise Mimetic
Following humanin’s discovery, additional MDPs have been identified within the mitochondrial genome. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino acid peptide encoded within the 12S rRNA gene that has emerged as a potent metabolic regulator. Research by Lee et al. (2015) demonstrated that MOTS-c promotes metabolic homeostasis, reduces obesity, and improves insulin resistance through activation of AMPK signaling in skeletal muscle. MOTS-c has been described as an βexercise mimeticβ due to its ability to recapitulate many of the metabolic benefits of physical exercise.
Small Humanin-Like Peptides (SHLPs 1β6)
Six additional small peptidesβSHLP1 through SHLP6βhave been identified within the 16S rRNA gene, the same mitochondrial region encoding humanin. These peptides exhibit diverse biological activities. SHLP2 and SHLP3 demonstrate cytoprotective and metabolic effects similar to humanin, while others show distinct functional profiles. SHLP2, in particular, has demonstrated chaperone-like activity against misfolded amyloid species, similar to HNG (Okada et al., 2017).
Implications for Mitochondrial Biology
The discovery of the MDP superfamily has fundamentally expanded our understanding of the mitochondrial genome’s coding capacity. Rather than being limited to 13 structural proteins, the mitochondrial genome contains numerous small ORFs encoding biologically active peptides that function as retrograde signalsβcommunicating mitochondrial status to the nucleus, other organelles, and distant tissues through endocrine signaling. This concept represents a paradigm shift in mitochondrial biology with implications for understanding aging, metabolic disease, and neurodegeneration.
Current Research Frontiers and Laboratory Applications
Chaperone-Mediated Autophagy
Recent research has identified humanin as an endogenous activator of chaperone-mediated autophagy (CMA), a selective protein degradation pathway that declines with age. Gong et al. (2018) demonstrated that humanin enhances CMA activity, providing a mechanistic link between humanin’s cytoprotective effects and cellular protein quality controlβa process critical for preventing age-related protein aggregation diseases.
Biomarker Applications
Humanin’s age-dependent decline and disease-associated changes position it as a potential biomarker for mitochondrial function, aging status, and disease risk. Research has demonstrated correlations between humanin levels and mitochondrial DNA copy number, MELAS heteroplasmy, and cardiovascular risk parameters.
Ongoing Areas of Investigation
Active areas of humanin peptide research include:
Blood-brain barrier penetration and CNS delivery optimization
Combination strategies with other MDPs (MOTS-c, SHLPs)
Gene therapy approaches using humanin overexpression constructs
Epigenetic regulation of humanin expression by environmental factors
Species-specific analogs for comparative aging research
Frequently Asked Questions About Humanin Peptide Research
What is humanin and how was it discovered?
Humanin is a 24-amino acid mitochondrial-derived peptide (MDP) first discovered in 2001 by Hashimoto et al. while screening for neuroprotective factors in the brain tissue of an Alzheimer’s disease patient. It is encoded by a small open reading frame within the 16S rRNA gene of the mitochondrial genome and represents the founding member of the MDP superfamily. Humanin peptide research has since expanded to encompass neuroprotection, cardiovascular protection, metabolic regulation, and aging biology. All humanin-related compounds are intended for research purposes only.
What makes humanin a mitochondrial-derived peptide?
Humanin is encoded within the mitochondrial genome, specifically within the MT-RNR2 gene (16S rRNA). Unlike the 13 canonical mitochondrial proteins involved in oxidative phosphorylation, humanin is a small peptide encoded by a previously unrecognized open reading frame. Evidence supporting its mitochondrial origin includes RNA hybridization data, the absence of humanin transcripts in Ο0 cells lacking mitochondrial DNA, and enhanced activity of N-formylated humaninβa hallmark of mitochondrial translation.
How does humanin exert its cytoprotective effects?
Research has identified at least four major signaling mechanisms: (1) direct binding and antagonism of the pro-apoptotic protein BAX; (2) high-affinity binding to IGFBP-3, neutralizing its pro-apoptotic activity; (3) activation of the JAK/STAT3 pathway through a trimeric CNTFR/WSX-1/gp130 receptor complex; and (4) agonism of the G-protein-coupled receptor FPRL1, activating ERK1/2 signaling. These combined mechanisms make humanin one of the most versatile cytoprotective peptides discovered.
What is HNG (S14G-humanin) and why is it important for research?
HNG is a synthetic humanin analog featuring a single amino acid substitution (serine to glycine at position 14) that increases biological potency by approximately 1,000-fold compared to native humanin. Because native humanin has a half-life of only ~30 minutes in circulation, HNG enables practical in vivo research at lower doses with sustained biological activity. It has been used in published studies investigating cardiovascular protection, cognitive decline, and metabolic improvement.
What has humanin research revealed about Alzheimer’s disease?
Humanin was originally discovered through its ability to protect neurons from Alzheimer’s disease-related toxicities. Research has demonstrated that humanin and its analogs protect against AΞ²-induced neuronal death, reduce amyloid-Ξ² accumulation and tau phosphorylation in transgenic AD mouse models, and improve cognitive outcomes. Notably, humanin levels in the cerebrospinal fluid of AD patients are significantly lower than in controls, suggesting a potential role as both a protective factor and biomarker.
How does humanin relate to aging and longevity?
Circulating humanin levels decline with age across mice, monkeys, and humans. However, children of centenariansβwho have a higher probability of exceptional longevityβdemonstrate significantly elevated humanin levels compared to age-matched controls. The naked mole-rat, a species exhibiting negligible senescence, maintains stable humanin levels over decades. In C. elegans, humanin overexpression is sufficient to extend lifespan in a daf-16/FOXO-dependent manner.
What is the MDP superfamily?
The mitochondrial-derived peptide superfamily includes humanin, MOTS-c (encoded in the 12S rRNA gene), and six small humanin-like peptides (SHLPs 1β6, encoded in the 16S rRNA gene). These peptides represent a novel class of retrograde signaling molecules through which mitochondria communicate with the nucleus and distant tissues. Each MDP has distinct but overlapping biological activities spanning cytoprotection, metabolic regulation, and stress resistance. For more details, see our Peptide Glossary.
Are there safety considerations in humanin cancer research?
Research indicates a complex dual role for humanin in cancer biology. While humanin protects normal cells from apoptosis and chemotherapy-induced damage, its cytoprotective mechanisms can also potentially promote tumor cell survival and chemoresistance. However, the HNG analog has been shown to protect normal tissues during chemotherapy without compromising anti-tumor efficacy in certain models. This area remains under active investigation.
Conclusion: The Future of Humanin Peptide Research
Humanin stands as a landmark discovery that has reshaped our understanding of mitochondrial biology, cellular protection, and the molecular mechanisms underlying aging and disease. From its origins in a Japanese laboratory screening for Alzheimer’s neuroprotective factors, humanin peptide research has expanded into a sprawling field spanning neuroscience, cardiovascular medicine, endocrinology, oncology, and gerontology.
The data are compelling: humanin declines with age, is elevated in the longest-lived individuals, extends lifespan in model organisms, and protects against a remarkable spectrum of disease-related insults. Its synthetic analogsβparticularly HNG and HNGF6Aβhave enabled researchers to probe these mechanisms with precision and reproducibility across multiple model systems.
As the MDP superfamily continues to expand and new members are characterized, the concept of the mitochondrial genome as a source of bioactive signaling peptides will undoubtedly yield further discoveries with therapeutic and diagnostic implications. For researchers investigating humanin, MOTS-c, SHLPs, and related mitochondrial-derived peptides, access to high-purity, research-grade compounds is essential.
Explore Iron Peak Peptides’ comprehensive catalog of research peptides, including humanin and related compounds, at Shop Iron Peak Peptides. All products are manufactured for research purposes only and are accompanied by quality assurance and third-party purity verification.
Research References
Hashimoto Y, Niikura T, Tajima H, et al. βA rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Abeta.β Proceedings of the National Academy of Sciences, 98(11), 6336β6341, 2001. DOI: 10.1073/pnas.101133498
Guo B, Zhai D, Cabezas E, et al. βHumanin peptide suppresses apoptosis by interfering with Bax activation.β Nature, 423(6938), 456β461, 2003. DOI: 10.1038/nature01627
Ikonen M, Liu B, Hashimoto Y, et al. βInteraction between the Alzheimer’s survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis.β Proceedings of the National Academy of Sciences, 100(22), 13042β13047, 2003. DOI: 10.1073/pnas.2135111100
Luciano F, Zhai D, Bhatt K, et al. βCytoprotective peptide humanin binds and inhibits proapoptotic Bcl-2/Bax family protein BimEL.β Journal of Biological Chemistry, 280(16), 15825β15835, 2005. DOI: 10.1074/jbc.M413062200
Hashimoto Y, Kurita M, Aiso S, et al. βHumanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor alpha/WSX-1/gp130.β Molecular Biology of the Cell, 20(12), 2864β2873, 2009. DOI: 10.1091/mbc.E09-02-0168
Muzumdar RH, Huffman DM, Atzmon G, et al. βHumanin: a novel central regulator of peripheral insulin action.β PLoS ONE, 4(7), e6334, 2009. DOI: 10.1371/journal.pone.0006334
Muzumdar RH, Huffman DM, Calvert JW, et al. βAcute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice.β Arteriosclerosis, Thrombosis, and Vascular Biology, 30(10), 1940β1948, 2010. DOI: 10.1161/ATVBAHA.110.205997
Bachar AR, Scheber L, Bhatt AS, et al. βHumanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress.β Cardiovascular Research, 88(2), 360β366, 2010. DOI: 10.1093/cvr/cvq191
Oh YK, Bachar AR, Bhatt DG, et al. βHumanin preserves endothelial function and prevents atherosclerotic plaque progression in hypercholesterolemic ApoE deficient mice.β Atherosclerosis, 219(1), 65β73, 2011. DOI: 10.1016/j.atherosclerosis.2011.06.038
Hoang PT, Park P, Cobb LJ, et al. βThe neurosurvival factor Humanin inhibits beta-cell apoptosis via signal transducer and activator of transcription 3 activation and delays and ameliorates diabetes in nonobese diabetic mice.β Metabolism, 59(3), 343β349, 2010. DOI: 10.1016/j.metabol.2009.08.001
Niikura T, Sidahmed E, Bhatt MP, et al. βA humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice.β PLoS ONE, 6(1), e16259, 2011. DOI: 10.1371/journal.pone.0016259
Lee C, Yen K, Cohen P. βHumanin: a harbinger of mitochondrial-derived peptides?β Trends in Endocrinology & Metabolism, 24(5), 222β228, 2013. DOI: 10.1016/j.tem.2013.01.005
Okada AK, Teranishi K, Lobo F, et al. βThe mitochondrial-derived peptides, HumaninS14G and small humanin-like peptide 2, exhibit chaperone-like activity.β Scientific Reports, 7, 7802, 2017. DOI: 10.1038/s41598-017-08372-5
Yen K, Mehta HH, Kim SJ, et al. βThe mitochondrial derived peptide humanin is a regulator of lifespan and healthspan.β Aging, 12(12), 11185β11199, 2020. DOI: 10.18632/aging.103534
Research Disclaimer
The information presented in this article is intended for educational and research purposes only. All peptides discussed are sold exclusively for laboratory research use and are not intended for human consumption, therapeutic application, or diagnostic use. The content herein does not constitute medical advice and should not be used as a basis for treatment decisions. Researchers should consult applicable regulations and institutional guidelines before initiating any studies. Iron Peak Peptides is committed to supporting legitimate scientific inquiry and adheres to all applicable laws governing the sale and distribution of research peptides.
🔬 Explore Research Peptides
- TB-500 10mg — $69.99
- VIP 10mg — $79.00
- Ipamorelin 10mg — $52.99
- GHRP-6 10mg — $39.00
